Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Angiotensin Receptor Blockers Market: By Product, By Application, By End User, and Geography
Angiotensin Receptor Blockers Market: By Product, By Application, By End User, and Geography
Angiotensin Receptor Blockers (ARBs) Market size was valued at US$ 8,449.9 million in 2023 and is expected to grow at a 4.9% CAGR from 2024 to 2030. Angiotensin receptor antagonists are drugs used in the treatment of hypertension, heart failure, and nephropathy. Angiotensin receptor blockers are widely used in the treatment of heart failure in patients who are unable to tolerate ACE inhibitors and have different potencies in blood pressure regulations with different effects at maximal doses. The increasing prevalence of diabetes and hypertension is expected to drive the growth of the angiotensin receptor blockers market over the forecast period. For instance, according to the World Health Organization, blood pressure is the most prevalent cause of heart failure resulting in rising mortality rates. In addition, this drug is widely used in the treatment of hypertension as it helps to widen the blood arteries and lower the blood pressure and has low side effects compared to other drugs. Furthermore, the increasing incidence of obesity in the young population along with chronic kidney disease drugs is expected to boost the angiotensin receptor blockers market growth. However, the patent expiry of antihypertensive drugs is anticipated to hinder the growth of the angiotensin receptor blockers market. For instance, in 2018, the FDA recalled the list of valsartan drugs as it is linked to cancer and is expected to affect the growth of the angiotensin receptor blockers market. Moreover, major market players operating in the angiotensin receptor blocker market are focused on developing innovative solutions to improve their position in the market. For instance, in 2021, Novartis AG launched Entresto(sacubitril/valsartan), which was approved by the FDA to reduce the risk of cardiovascular death. These factors are anticipated to provide angiotensin receptor blockers market opportunities to the key players and manufacturers in the growth of angiotensin receptor blockers over the forecast period.
Study Period
2024-2030Base Year
2023CAGR
4.9%Largest Market
North AmericaFastest Growing Market
Asia Pacific
The angiotensin receptor blockers market is expected to grow over the forecasted period due to the increasing prevalence of hypertension, cardiovascular diseases, and obesity. Hypertension is a prevalent condition affecting millions of lives across the globe and increasing the risk of serious cardiovascular disease such as myocardial infraction and stroke. For instance, according to the World Health Organization, hypertension affects one million people across the globe and is expected to increase by 60% which is 1.56 million by 2025. These factors are expected to drive the growth of angiotensin receptor blockers market over the forecast period. In addition, factors such as increasing geriatric population, rapid urbanization, unhealthy lifestyle choices, genetic predisposition are expected to boost the growth of angiotensin receptor blockers market.
The angiotensin receptor blockers market is segmented based on regions into North America, Asia-pacific, Europe, Latin America, and the Middle East and Africa. The North America angiotensin receptor blockers market is likely to hold a significant revenue share, and in the forecasted years, it is predicted to increase rapidly due to the increasing prevalence of cardiovascular diseases and kidney illness in this region. In addition, government initiatives in promoting awareness about the early treatment of disease is expected to boost the growth of angiotensin receptor blockers market in this region. Europe region is expected to have highest CAGR over the forecast period owing to increasing incidence of genetic disorders, uncommon diseases, and rising geriatric patients in this region.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 8,449.9 million |
|
Market CAGR |
4.9% |
|
By Product |
|
|
By Application |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
Angiotensin Receptor Blockers (ARBs) Market was valued at US$ 8,449.9 million in 2023.
Increasing prevalence of cardiovascular diseases, kidney disorders and rising geriatric patients are the factors expected to drive the growth of angiotensin receptor blockers market.
The leading players in the global Angiotensin Receptor Blockers (ARBs) market are Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., GSK Plc., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Otsuka Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Astellas Pharma Inc.
| 1. Executive Summary |
| 2. Global Angiotensin Receptor Blockers (ARBs) Market Introduction |
| 2.1.Global Angiotensin Receptor Blockers (ARBs) Market - Taxonomy |
| 2.2.Global Angiotensin Receptor Blockers (ARBs) Market - Definitions |
| 2.2.1.Product |
| 2.2.2.Application |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3. Global Angiotensin Receptor Blockers (ARBs) Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Angiotensin Receptor Blockers (ARBs) Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Angiotensin Receptor Blockers (ARBs) Market By Product, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Valsartan |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Telmisartan |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Losartan |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Irbesartan |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Olmesartan |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Others |
| 5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 6. Global Angiotensin Receptor Blockers (ARBs) Market By Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Hypertension |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Cardiovascular Diseases |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Kidney Diseases |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Others |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 7.Global Angiotensin Receptor Blockers (ARBs) Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospital Pharmacies |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacies |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Online Pharmacies |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8. Global Angiotensin Receptor Blockers (ARBs) Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9. North America Angiotensin Receptor Blockers (ARBs) Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Product Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Valsartan |
| 9.1.2.Telmisartan |
| 9.1.3.Losartan |
| 9.1.4.Irbesartan |
| 9.1.5.Olmesartan |
| 9.1.6.Others |
| 9.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Hypertension |
| 9.2.2.Cardiovascular Diseases |
| 9.2.3.Kidney Diseases |
| 9.2.4.Others |
| 9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospital Pharmacies |
| 9.3.2.Retail Pharmacies |
| 9.3.3.Online Pharmacies |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10. Europe Angiotensin Receptor Blockers (ARBs) Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Valsartan |
| 10.1.2.Telmisartan |
| 10.1.3.Losartan |
| 10.1.4.Irbesartan |
| 10.1.5.Olmesartan |
| 10.1.6.Others |
| 10.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Hypertension |
| 10.2.2.Cardiovascular Diseases |
| 10.2.3.Kidney Diseases |
| 10.2.4.Others |
| 10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospital Pharmacies |
| 10.3.2.Retail Pharmacies |
| 10.3.3.Online Pharmacies |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11. Asia Pacific (APAC) Angiotensin Receptor Blockers (ARBs) Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Valsartan |
| 11.1.2.Telmisartan |
| 11.1.3.Losartan |
| 11.1.4.Irbesartan |
| 11.1.5.Olmesartan |
| 11.1.6.Others |
| 11.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Hypertension |
| 11.2.2.Cardiovascular Diseases |
| 11.2.3.Kidney Diseases |
| 11.2.4.Others |
| 11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospital Pharmacies |
| 11.3.2.Retail Pharmacies |
| 11.3.3.Online Pharmacies |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12. Middle East and Africa (MEA) Angiotensin Receptor Blockers (ARBs) Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Valsartan |
| 12.1.2.Telmisartan |
| 12.1.3.Losartan |
| 12.1.4.Irbesartan |
| 12.1.5.Olmesartan |
| 12.1.6.Others |
| 12.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Hypertension |
| 12.2.2.Cardiovascular Diseases |
| 12.2.3.Kidney Diseases |
| 12.2.4.Others |
| 12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospital Pharmacies |
| 12.3.2.Retail Pharmacies |
| 12.3.3.Online Pharmacies |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13. Latin America Angiotensin Receptor Blockers (ARBs) Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Valsartan |
| 13.1.2.Telmisartan |
| 13.1.3.Losartan |
| 13.1.4.Irbesartan |
| 13.1.5.Olmesartan |
| 13.1.6.Others |
| 13.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Hypertension |
| 13.2.2.Cardiovascular Diseases |
| 13.2.3.Kidney Diseases |
| 13.2.4.Others |
| 13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospital Pharmacies |
| 13.3.2.Retail Pharmacies |
| 13.3.3.Online Pharmacies |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M&A, Strategies, and SWOT Analysis) |
| 14.2.1.Pfizer Inc. |
| 14.2.2.Novartis AG |
| 14.2.3.Merck & Co. Inc. |
| 14.2.4.AstraZeneca Plc. |
| 14.2.5.GSK Plc. |
| 14.2.6.Bristol-Myers Squibb Company |
| 14.2.7.Teva Pharmaceutical Industries Ltd. |
| 14.2.8.Daiichi Sankyo Company Limited |
| 14.2.9.Lupin Limited |
| 14.2.10.Otsuka Pharmaceutical Co. Ltd. |
| 14.2.11.Dr. Reddy’s Laboratories Ltd. |
| 14.2.12.Astellas Pharma Inc. |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.